NovaQuest’s partners have found an interesting way to invest in pharmaceuticals at a time when neither the focus on healthcare nor the potential for treatment of rare diseases have been greater.
“We are investing in the late stages of R&D and commercialization of pharmaceutical products,” said Jonathan Tunnicliffe, the founding partner and chief investment officer of NovaQuest Capital Management.
We're not trying to underwrite the science. We're looking to interpret the data.
Jonathan tunnicliffe
The investment firm was founded as part of Quintiles, now known as . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
